BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) – Equities research analysts at HC Wainwright lowered their FY2025 EPS estimates for BriaCell Therapeutics in a report released on Thursday, October 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.58) per share for the year, down from their previous forecast of ($0.26). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.19) EPS and FY2029 earnings at ($0.11) EPS.
BriaCell Therapeutics Trading Up 0.9 %
Shares of BriaCell Therapeutics stock opened at $1.08 on Monday. The company has a fifty day simple moving average of $0.72 and a 200-day simple moving average of $1.35. The stock has a market cap of $19.75 million, a price-to-earnings ratio of -0.86 and a beta of 1.34. BriaCell Therapeutics has a 12-month low of $0.46 and a 12-month high of $6.10.
Institutional Trading of BriaCell Therapeutics
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Articles
- Five stocks we like better than BriaCell Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Why Are Stock Sectors Important to Successful Investing?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What is a Stock Market Index and How Do You Use Them?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.